Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Waterhouse, David
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer	Recruiting	3	670	Europe, Canada, Japan, US, RoW	sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel	Seagen, a wholly owned subsidiary of Pfizer	Carcinoma, Non-Small-Cell Lung	03/26	03/28
Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients	Recruiting	1/2	62	US	quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ	Genprex, Inc.	Small Cell Lung Cancer Extensive Stage	02/26	08/27
RegStud, NCT06335758: Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.	Recruiting	N/A	1000	US	Use of ReX to dispense and monitor solid oral medication therapy.	Dosentrx Ltd., US Oncology Research	Any Solid Oral Medication	12/25	01/26
Strahs, Deborah
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Waterhouse, David
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer	Recruiting	3	670	Europe, Canada, Japan, US, RoW	sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel	Seagen, a wholly owned subsidiary of Pfizer	Carcinoma, Non-Small-Cell Lung	03/26	03/28
Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients	Recruiting	1/2	62	US	quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ	Genprex, Inc.	Small Cell Lung Cancer Extensive Stage	02/26	08/27
RegStud, NCT06335758: Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.	Recruiting	N/A	1000	US	Use of ReX to dispense and monitor solid oral medication therapy.	Dosentrx Ltd., US Oncology Research	Any Solid Oral Medication	12/25	01/26
Strahs, Deborah
No trials found